Gender Differences in 3-Month Outcomes of Erenumab Treatment—Study on Efficacy and Safety of Treatment With Erenumab in Men

Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment – real world outcomes

(2021) J. Talbot et al.   JOURNAL OF HEADACHE AND PAIN

Changing levels of sex hormones and calcitonin gene-related peptide (CGRP) during a woman’s life: Implications for the efficacy and safety of novel antimigraine medications

(2021) Simone de Vries Lentsch et al.   MATURITAS

Migraine: disease characterisation, biomarkers, and precision medicine

(2021) Messoud Ashina et al.   LANCET

Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy

(2020) Raffaele Ornello et al.   JOURNAL OF HEADACHE AND PAIN

Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study

(2020) Bianca Raffaelli et al.   Frontiers in Neurology

Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience

(2020) Antonio Russo et al.   JOURNAL OF HEADACHE AND PAIN

A prospective real-world analysis of erenumab in refractory chronic migraine

(2020) Giorgio Lambru et al.   JOURNAL OF HEADACHE AND PAIN

Erenumab in highly therapy-refractory migraine patients: First German real-world evidence

(2020) Armin Scheffler et al.   JOURNAL OF HEADACHE AND PAIN

Erenumab in Chronic Migraine: An Australian Experience

(2020) Shuli Cheng et al.   HEADACHE

Erenumab efficacy in highly resistant chronic migraine: a real-life study

(2020) Umberto Pensato et al.   NEUROLOGICAL SCIENCES

One year experience with erenumab: real-life data in 30 consecutive patients

(2020) Angelo Ranieri et al.   NEUROLOGICAL SCIENCES

Erenumab in the prevention of high‐frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real‐life study

(2020) Piero Barbanti et al.   HEADACHE

European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

(2019) Simona Sacco et al.   JOURNAL OF HEADACHE AND PAIN

How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice

(2019) Cindy Tiseo et al.   JOURNAL OF HEADACHE AND PAIN

Epidemiology of migraine in men: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study

(2018) Ann I Scher et al.   CEPHALALGIA

CGRP as the target of new migraine therapies — successful translation from bench to clinic

(2018) Lars Edvinsson et al.   Nature Reviews Neurology

CGRP Antibodies as Prophylaxis in Migraine

(2018) Lars Edvinsson   CELL

Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study

(2018) Uwe Reuter et al.   LANCET

Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

(2018) Lars Jacob Stovner et al.   LANCET NEUROLOGY

Sex differences in the epidemiology, clinical features, and pathophysiology of migraine

(2017) Kjersti Grøtta Vetvik et al.   LANCET NEUROLOGY

Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial

(2017) Stewart Tepper et al.   LANCET NEUROLOGY

A Controlled Trial of Erenumab for Episodic Migraine

(2017) Peter J. Goadsby et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sex and the migraine brain

(2014) D. Borsook et al.   NEUROBIOLOGY OF DISEASE